Brief: Alector Announces Topline Results From Latozinemab Phase 3 Trial In Individuals With Frontotemporal Dementia Due To A Grn Mutation And Provides Business Update
21/10/2025 21:49
Oct 21 (Reuters) - Alector Inc ALEC.O: ALECTOR ANNOUNCES TOPLINE RESULTS FROM LATOZINEMAB PHASE 3 TRIAL IN INDIVIDUALS WITH FRONTOTEMPORAL DEMENTIA DUE TO A GRN MUTATION AND PROVIDES BUSINESS UPDATE ALECTOR INC - LATOZINEMAB FAILS TO MEET CLINICAL ENDPOINT IN FTD-GRN TRIAL ALECTOR INC - DISCONTINUES OPEN-LABEL EXTENSION FOR LATOZINEMAB ALECTOR INC - TO REDUCE WORKFORCE BY ABOUT 49% Source text: ID:nGNX184DrP Further company coverage: ALEC.O ((Reuters.Briefs@thomsonreuters.com;))